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Background: Fecal alpha-1-antitrypsin (AAT) clearance has been a marker of clinical disease severity in inflammatory bowel diseases (IBDs) for many
years. Although AAT deficiency is more often associated with lung and liver pathologies, AAT-deficient patients with concomitant IBD have been
shown to develop more aggressive disease and rapid progression to surgery. Although recent studies have highlighted the pleiotropic anti-inflammatory
functions of AAT, including reducing proinflammatory cytokine production and suppressing immune cell activation, its potential therapeutic role in IBD
has not been described.
Methods: The therapeutic potential of human AAT administration was assessed in murine models of IBD including new-onset and established
chemically induced colitis and spontaneous chronic murine ileitis. Histological assessment of inflammation, cytokine secretion profiling, and flow
cytometric evaluation of inflammatory infiltrate were performed in each model. The effect of AAT on intestinal barrier function was also examined both
in vitro and in vivo.
Results: AAT attenuated inflammation in small and large intestinal IBD models through reduced secretion of proinflammatory cytokines, inflammatory
cell infiltration, and reduced tissue injury. AAT also increased intestinal restitution after chemically induced colitis. AAT significantly decreased
intestinal permeability in vitro and in vivo as part of a protective mechanism for both acute and chronic models of IBD.
Conclusions: Our findings describe a beneficial role for AAT in IBD models through suppression of cytokine production and enhanced intestinal
barrier function. This raises the possibility that AAT supplementation, which has a long history of proven safety, may have a therapeutic effect in
human IBD.
(Inflamm Bowel Dis 2013;19:1964–1973)
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T he inflammatory bowel diseases (IBD), i.e., ulcerative colitis(UC) and Crohn’s disease (CD), are likely initiated by envi-
ronmental factors (e.g., bacterial antigens), which trigger a dysre-
gulated immune response in genetically predisposed hosts.1 This
response is characterized by imbalanced effector and regulatory
mechanisms reflected by a preponderance of proinflammatory
cytokines within intestinal tissues. Clinically, there is an unmet
need for newer therapies as the efficacy of tumor necrosis factor
(TNF)-a neutralization induces remission at best in 50% to 70%
of patients and sustained remission drops significantly at 1 year.2
Although the direct correlation between fecal alpha-1-
antitrypsin (AAT) and disease activity in CD has been well
documented for approximately 30 years,3 the possibility that this
increased loss of AAT might be detrimental in IBD has not been
fully explored. AAT is a 418 amino acid serine protease inhibitor,
primarily synthesized and secreted by hepatocytes.4 It is also
transcribed and secreted by neutrophils, macrophages, monocytes,
enterocytes,5 and Paneth cells.6 Its best-described function is to
protect tissues from the proteolytic activity of neutrophil elastase.
This is particularly evident in the lung, where AAT deficiency
results in panacinar emphysema.4 Despite being the most abundant
protease inhibitor in the circulation, it increases from 2-fold to
3-fold in response to lung inflammation, suggesting that rather than
being constitutive, AAT expression can be upregulated in response
to inflammatory cues. A growing body of evidence demonstrates
that AAT plays additional roles at extrapulmonary and extrahepatic
sites. AAT protects pancreatic beta cells from apoptosis,7 inhibits
proinflammatory cytokine production8 and metalloproteinases,9
reverses diabetes in non-obese diabetic mice,10 induces immune
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tolerance during islet allograft transplantation,11,12 and prolongs
islet allograft survival in mice and transplanted organs from graft-
versus-host disease.13
Although AAT deficiency is approximately 10 times less
frequent than IBD in North America, a retrospective study
demonstrated that 9 of 10 patients with concomitant UC and
AAT deficiency were refractory to medical therapy and required
colectomy, suggesting that endogenous AAT may have a pro-
tective role in the intestine.14 Yet, to our knowledge, this concept
has not been explored in preclinical models of IBD. Given the
pleiotropic anti-inflammatory effects of AAT, we hypothesized
that administration of human plasma-derived AAT (hAAT) might
attenuate experimental IBD.
In the current studies, we first assessed the therapeutic
potential of hAAT an acute chemically induced (i.e., dextran
sulfate sodium [DSS]) model of colitis, which is predominantly
mediated by innate immune mechanisms and is characterized by
superficial ulcerations limited to the colonic mucosa: 2 features
that are shared with human UC.15,16 We next assessed the benefit
of hAAT administration in a more clinically relevant model of
recovery from established chemically induced colitis. Thereafter,
we demonstrated a protective effect in the SAMP1 chronic model
in which mice spontaneously develop idiopathic segmental trans-
mural ileitis17 that recapitulate many features of CD. We charac-
terized the impact of AAT administration on intestinal barrier
function a feature that reflects both cause and consequence of
intestinal inflammation in these models. Finally, we demonstrated
an upregulation of AAT in patients with CD consistent with
a potential compensatory anti-inflammatory mechanism.
MATERIALS AND METHODS
Induction of Chemically induced Colitis
Mice were administered DSS (3% wt/vol; 36–50 kDa; MP
Biomedicals, Solon, OH) in drinking water ad libitum for 7 days.
Water alone was used for vehicle groups. DSS groups received
intraperitoneal injections of either 2 mg/day hAAT (Aralast NP;
Baxter, Thousand Oaks, CA or Prolastin C; Talecris, Durham, NC)
or human serum albumin. Mice were weighed daily and a disease
activity index (DAI) was calculated for each mouse, based on
weight loss, occult blood, and stool consistency. A score of 1 to
4 was given for each parameter, with a maximum DAI score of 12.
At the time of killing, spleen, mesenteric lymph nodes (MLN), and
segments of colonic tissue were excised for flow cytometric anal-
ysis of leukocyte subsets. Colon sections (distal to cecum) were
also excised, opened longitudinally, and fixed in 10% buffered
formalin; paraffin embedded, cut into 3 to 5 mm sections, and
stained with hematoxylin/eosin. The severity of colitis was assessed
by a pathologist (P.J.) blinded to the treatment groups, as per pub-
lished methods.18,19 Additionally, colon lengths were recorded and
colon explants cultured for 24 hours in complete RPMI media
(supplemented with 5% fetal bovine serum, 100 IU penicillin,
and 100 mg/mL streptomycin; Invitrogen, Carlsbad, CA).
Recovery from DSS Colitis
Mice were treated with DSS for 9 days, replacing with fresh
DSS every 3 days. Once mice had reached the desired target weight
loss (15%), DSS was withdrawn. Subsequent recovery of weight
was recorded daily and used as a surrogate indicator of mucosal
healing. Treatment groups received daily intraperitoneal injections
of either 2 mg hAAT (Aralast NP; Baxter or Prolastin C; Talecris) or
human serum albumin on establishment of disease. Due to the lack
of frequent bowel movements during the initial phase of recovery
from DSS colitis, DAI were not calculated for those studies.
Treatment of Spontaneous Chronic Ileitis
Twenty-week-old SAMP1 mice from a colony bred by
Dr Rivera-Nieves were treated intraperitoneally for 9 days with
2 mg/day hAAT (Prolastin C; Talecris) or human serum
albumin. Terminal ileal tissues were harvested for histological
evaluation of inflammation and leukocyte isolation before flow
cytometric assessment.
Lymphocyte and Epithelial Cell Isolation
Single-cell suspensions were obtained by passage of the
MLN or spleen through a 100-mm cell strainer. Splenic red blood
cells were lysed by incubation in ammonium chloride lysing
reagent (ACK Lysis Buffer; Invitrogen). Intestinal segments were
opened along the mesentery and rinsed of luminal contents with
PBS before cutting into 1 cm sections in PBS containing 15 mM
HEPES and 1 mM EDTA and processed with vigorous agitation
on a vortex mixer. The tissue was then passed through a 70-mm
tissue strainer, and the process repeated until the wash remained
clear. The remaining lamina propria (LP) was digested in 1 mg/mL
Collagenase Type VIII (C9722; Sigma–Aldrich, St. Louis, MO) for
20 minutes in an orbital shaker at 270 rpm and 378C. Tissues were
vortexed briefly and filtered to remove any remaining undigested
material and cells counted before flow cytometric evaluation.
Flow Cytometry
Cells from indicated compartments were incubated with
fluorescent rat anti-mouse antibodies including against: mouse CD4
(RM4-5), CD8 (53-6.7), CD19 (1D3), Nk1.1 (PK136), CD11c
(N418), MHCII (M5/114.15.2), F4/80 (BM8), Siglec F (E50-2440),
and GR-1 (RB6-8C5). Cells were washed and fixed with 2%
paraformaldehyde and analyzed using the BD FACSCantoII system
(Beckton-Dickinson Immunocytometry Systems, San José, CA).
Results were expressed as percentage of total live cells recovered
from indicated organs. Absolute numbers of cells were described
separately as cellularity of the intestinal tissue. Post-analyses were
performed using FLOWJo software (Tree Star, Inc., Ashland, OR).
Cytokine Production Assays
To assess cytokine secretion from the inflamed intestines,
tissue explants (0.5 cm2) were cultured for 24 hours in Dulbecco’s
modified Eagles medium (without sodium pyruvate; Cellgro, Man-
assas, VA, supplemented with 5% fetal bovine serum, 2 mM gluta-
mine, 100 IU penicillin, and 100 mg/mL streptomycin; Invitrogen).
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Culture supernatants were then analyzed for the presence of cyto-
kines with reduced background protein levels compared with tissue
homogenates using the highly sensitive Quansys Cytokine Assay
System (Logan, UT). Results were then expressed relative to the
initial wet weight of the intestinal tissue explants.
Transepithelial Electrical Resistance Assays
Human colonic epithelial cells (T84; a gift from Dr. Stephen
Keely; UCD, Dublin, Ireland) were cultured as previously
described.18 Briefly, T84 cells (0.5 · 106) were cultured on
6.5-mm polyester permeable Transwell membranes (0.4-mm pore;
Costar, Cambridge, MA) for 7 to 10 days to allow for formation of
a monolayer with appropriate barrier function, as measured by
transepithelial electrical resistance (TEER). Quadruplicate wells
were incubated on both sides with control (media alone), hAAT
(0.5 mg/mL), DSS (3%), or combined treatment. TEER measure-
ments were taken 6 hours posttreatment using an Evom (World
Precision Instruments, Sarasota, FL).
Endothelial Cell Permeability Assay
Human microvascular endothelial cells (Biological Prod-
ucts Branch, Centers for Disease Control, Atlanta, GA) were
incubated at 378C and 5% CO2 and cultured as recommended.
19
Macromolecule permeability was measured as previously
described20 with slight modifications. Briefly, human microvascu-
lar endothelial cells were seeded on 0.4-mm Transwells as above
at 1 · 106 cells per insert and allowed to reach confluency. Inserts
were placed in Ca2+-containing Hanks-buffered saline solution
with or without lipopolysaccharide (10 mg/mL; List Laboratories,
Campbell, CA), hAAT (0.5 mg/mL), or both. Following either 6
or 24 hours LPS treatment, fluorescein isothiocyanate-labeled
dextran 70 kDa (FD70, 7 mM; Sigma–Aldrich) was added to
the upper chamber of each insert. At time points of 20, 40, and
60 minutes, 50 ml of sample was collected and fluorescence mea-
sured using a Cytofluor 2300 fluorimeter (Millipore Corp.,
Bedford, MA). FD70 concentrations were determined from serial
dilution and flux rates calculated by linear regression. Data were
then normalized and plotted as fold increase over the observed
flux rate in untreated endothelial monolayers.
In Vivo Intestinal Permeability Assays
Flux of fluorescein isothiocyanate-dextran sugar was used
as a surrogate marker of intestinal permeability. Mice received
200 ml of fluorescein isothiocyanate-labeled dextran 4 kDa (FD4;
20 mg/kg; Sigma–Aldrich) by gavage, and serum samples taken
4 hours later were assayed by a fluorimeter.
AAT Detection
Human AAT messenger RNA transcript was measured in
complementary DNA from control and patients with CD on the
TissueScan complementary DNA array (Origene Technologies,
Rockville, MD) using Taqman probes (Life Technologies, Grand
Island, NY) for both AAT and b-actin as an endogenous control.
Disease distribution was determined using clinical and pathological
information provided by Origene Technologies for each sample.
Paraffin-embedded sections from archived human tissue of patients
definitively diagnosed with(out) CD were obtained under research
protocols approved by the Colorado Multi-Institutional Review
Board. These were immunostained using the monoclonal anti-
human AAT antibody (1102) (Thermo Fisher Scientific, Rockford,
IL) according to the manufacturer’s instructions.
Statistics
Statistical analyses were performed using Student’s t test or 2-
way analysis of variance with Bonferroni posttests with GraphPad
Prism Data Analysis software (GraphPad Software, La Jolla, CA).
Data were expressed as mean 6 standard error of the mean. Statis-
tical significance was set at a P value ,0.05.
RESULTS
hAAT Protects Mice from Clinical Signs
of Colitis
Based on the known anti-inflammatory role of hAAT and
the association between loss of AAT and disease severity, we
chose to assess the therapeutic benefit of AAT supplementation in
murine preclinical models. We began by assessing the impact of
hAAT administration on acute murine colitis. Mice treated with
hAAT lost less weight in response to DSS administration
compared with albumin-treated mice. Weights at time of killing
(day 7) decreased to 84.4 6 1.0% of initial body weight in
vehicle-treated mice compared with 93.7 6 0.9% in hAAT-treated
FIGURE 1. Alpha-1-antitrypsin protected mice from acute colitis. A,
Assessment of DSS-induced weight loss in mice treated with albumin or
hAAT. B, Measurement of clinical disease activity including weight loss,
fecal consistency, and rectal bleeding of albumin and hAAT-treated
DSS-challenged mice. C, Colon length of water control, albumin-injected
DSS-treated mice, and mice receiving DSS and hAAT. D, Representative
photograph of DSS-induced injury in albumin-treated and hAAT-treated
mice. Data expressed as mean 6 standard error of the mean, n ¼ 6
mice per group; *P , 0.05, **P , 0.01, ***P , 0.001.
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mice (P , 0.001) (Fig. 1A). Additionally, at day 7, we observed
a reduction of the DAI from 13.7 6 0.6 in albumin-treated mice to
8.0 6 0.6 in hAAT-treated mice (P , 0.001) (Fig. 1B) and a 20
percent decrease in colonic shortening in hAAT-treated mice com-
pared with albumin-treated mice (P, 0.01) (Fig. 1C). These differ-
ences were evident macroscopically (Fig. 1D). The concentration of
hAAT used for these and subsequent studies was chosen based on
the performance of a dose response to hAAT in DSS colitis (data not
shown). Based on its optimal performance, the dosage of 2 mg/mL/
day was therefore administered in subsequent therapeutic studies.
hAAT Ameliorates Histological Evidence of
Tissue Injury
Treatment with hAAT generated a significant decrease in
tissue damage indices, from 2.9 6 0.1 in vehicle-treated mice to
1.8 6 0.4 in hAAT-treated animals (P , 0.05) (Fig. 2A). The
decreased tissue damage was reflected by improved villus
architecture and reduced goblet cell hyperplasia, as seen in rep-
resentative micrographs (Fig. 2C). Although adaptive immunity
plays a less important role than innate immune cells in this acute
model, we observed a significant decrease in the percentage of
CD4+ T cell in the colonic LP of hAAT-treated mice (0.4 6
0.03%) following DSS compared with albumin controls (0.7 6
0.05% in DSS; P , 0.01), and similarly, CD19+ B cells decreased
in hAAT-treated (3.36 0.5%) mice relative to DSS controls (4.46
0.2%; P , 0.05) (Fig. 2D), although these differences were insuf-
ficient to affect overall cell numbers significantly. Thus, hAAT
administration decreased histological evidence of tissue damage
and decreased lymphocytic infiltration during acute colitis.
hAAT Suppresses Colonic Proinflammatory
Cytokine Production in DSS-treated Mice
Having demonstrated attenuation of colitis with hAAT, we
then cultured colonic explants of mice treated with DSS and albumin
FIGURE 2. hAAT attenuated histological indices of colitis. A, Histological scores of tissue damage and inflammatory cell infiltrate assessed by
a trained pathologist in a blinded fashion. B, Quantification of cellularity from indicated organs of water, albumin-treated DSS mice, or mice
receiving both DSS and hAAT. C, Representative micrographs showing attenuated inflammation by hAAT treatment in DSS colitic mice compared
with albumin-treated controls. D, Infiltration of T and B cells in the colonic LP assessed by multicolor flow cytometry. Data are expressed as
mean 6 standard error of the mean; *P , 0.05. Results are representative of 3 independent experiments with at least 6 mice per group in each
experiment.
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or hAAT, along with tissues from untreated controls (water) and
measured the cytokines released into the supernatants. Interleukin
(IL)-1b secretion from colonic explants of DSS colitis mice was
significantly higher than from water controls. This increase was sig-
nificantly attenuated in hAAT-treated mice (3.5 6 1.3 pg/mL/mg)
exposed to DSS relative to vehicle-treated DSS mice (9.1 6 2.7 pg/
mL/mg; P , 0.05) (Fig. 3). Similarly, IL-6, which was induced
in DSS, was significantly reduced in hAAT-treated tissues (6.1 6
1.1 ng/mL/mg) compared with vehicle-treated controls (10.0 6
1.0 ng/mL/mg; P , 0.05). Monocyte chemotactic protein-1
(MCP-1) was significantly higher from colitis explants, and once
again, this was significantly decreased in hAAT-treated colitic mice
(175.5 6 57 pg/mL/mg) relative to vehicle controls (420.8 6 43.6
pg/mL/mg; P, 0.01). Finally, CXCL1 was increased in response to
DSS but was lower in hAAT-treated tissues (4.2 6 1.2 ng/mL/mg)
compared with vehicle-treated DSS colitis (6.6 6 0.6 ng/mL/mg;
P , 0.05). Therefore, the inflammatory cytokine response induced
by DSS colitis was significantly blunted by hAAT administration.
hAAT Accelerates Mucosal Healing After
DSS-induced Injury
We then studied whether hAAT might have an effect, not
only on the prevention but also in the recovery from chemically
induced colonic injury. On establishment of inflammation of the
colonic mucosa, DSS was discontinued, and body weight was
monitored (Fig. 4A). Treatment with hAAT significantly
increased weight recovery of mice through day 13 when the dif-
ference in mean weight loss between treatment groups differed
from 10 6 0.9 in AAT-treated mice versus 15.6 6 0.6 in vehicle-
treated mice (n ¼ 5 per group; P, 0.01) (Fig. 4A). The increased
weight gain by hAAT-treated mice coincided with a significant
reduction in colon shortening from 53 6 2 mm in vehicle-treated
mice versus 69 6 3 mm in hAAT-treated mice (n ¼ 5; P , 0.05)
(Fig. 4B). Quantification of cells from DSS-treated mice demon-
strated that mice treated with hAAT had a significant increase in
the total numbers of cells in the spleen compared with from 50 ·
106 6 8.5 · 106 versus 70 · 106 6 8 · 106 (P , 0.05; n ¼ 5)
(Fig. 4C) and MLN from 14 · 106 6 3 · 106 in vehicle-treated
mice to 27 · 106 6 5 · 106 in hAAT-treated mice (P , 0.05)
(Fig. 4C). In contrast, there was a significant decrease in inflam-
matory infiltrate in the colonic LP of DSS-treated mice from 4 ·
106 6 5 · 105 in vehicle-treated mice versus 2 · 106 6 5.6 · 105
in hAAT-treated mice (P , 0.05) (Fig. 4C).
Decreased colonic shortening and colonic cell infiltrate was
accompanied by decreased inflammatory indices from 2.4 6 0.2 to
1.7 6 0.1 (P , 0.05) and tissue damage index of 2 6 0.3 versus
0.9 6 0.2 (P , 0.01; Fig. 4D). Multiplex analysis of cytokine
release from colonic explant cultures identified a significant hAAT-
mediated decrease in the release of IL-1b (6.2 6 1.5 pg/mL/mg
versus 0.8 6 0.4 pg/mL/mg; P , 0.01) (Fig. 4E) and interferon
g (3.5 6 1.5 pg/mL/mg versus 0.4 6 0.1 pg/mL/mg; P , 0.05).
Similarly, treatment with hAAT significantly decreased the release of
TNF-a (0.86 0.2 pg/mL/mg to 0.16 0.1 pg/mL/mg; P, 0.01) and
IL-17 (3.36 1.6 pg/mL/mg versus 0.36 0.1 pg/mL/mg; P, 0.05).
Finally, release of MCP-1 from colonic explants was significantly
reduced by hAAT administration (131.3 6 38.0 pg/mL/mg versus
64.3 6 15.2 pg/mL/mg; P , 0.05). Thus, 2 weeks after injury, we
additionally observe changes in lymphocyte-derived cytokines, sug-
gesting that AAT may not only attenuate acute inflammation but also
chronic inflammatory processes.
hAAT Administration Ameliorates Chronic
Ileitis in SAMP1 Mice
To further test the hypothesis that hAAT attenuates chronic
intestinal inflammation, we treated SAMP1 mice, a chronic ileitis
model that is predominantly mediated by adaptive immune
responses. hAAT attenuated chronic inflammation (4 6 0.8 ver-
sus 2.46 0.5; P, 0.05), villus distortion (4.66 0.7 versus 2.36
0.5; P, 0.05), and total inflammatory indices (146 2 versus 96
0.5; P , 0.05) (Fig. 5A) relative to albumin-treated controls. In
addition, histological hallmarks of ileitis, such as leukocyte infil-
tration, goblet cell hyperplasia, and muscularis hypertrophy were
noticeably decreased (Fig. 5B).
hAAT Decreased CD4+ T Cells in MLN and
Lamina Propria of SAMP1 Mice
We then examined whether hAAT might also decrease
lymphocyte recruitment to the ileal LP. Subset analysis of leukocytes
from the spleen, MLN, and ileal LP of SAMP1 mice treated with
hAAT or albumin demonstrated a significant decrease in the
proportion of CD4+ T lymphocytes in both the MLN (P , 0.01)
(Fig. 6A, B) and LP (P, 0.05). In contrast, there were no significant
changes in the proportions of CD8+ T lymphocytes, B cells, den-
dritic cells, macrophages, natural killer cells or natural killer T cells.
hAAT Decreased Proinflammatory Cytokines
in SAMP1 Ileum
Analysis of cytokine release from cultured ileal explants of
SAMP1mice treated with vehicle or hAAT demonstrated a significant
FIGURE 3. hAAT reduced cytokine secretion by colonic explants.
Assessment of cytokines released by colon tissue explants cultured for
24 hours in complete media from DSS-treated albumin or hAAT-
treated mice compared with control (water) mice. Data expressed as
mean 6 standard error of the mean, n ¼ 6 per group, *P , 0.05.
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decrease in TNF-a (0.08 6 0.03 pg/mL/mg versus 0.02 6
0.01 pg/mL/mg; P , 0.05), IL-17 (0.04 6 0.01 pg/mL/mg
versus 0 pg/mL/mg; P , 0.05), and CXCL1 (0.4 6 0.05
pg/mL/mg versus 0.1 6 0.06 pg/mL/mg; P , 0.01) (Fig. 6C).
Therefore, treatment of chronic murine ileitis with hAAT atten-
uated inflammation, decreased lymphocyte infiltration, and sup-
pressed proinflammatory cytokine secretion in a manner similar
to that seen in the murine colitis models.
hAAT Enhanced Intestinal Barrier Function
Both in vitro and in vivo
Having demonstrated a significant anti-inflammatory effect
of hAAT, we next sought to assess the impact of hAAT
administration on intestinal barrier function, based on the shared
role for barrier disruption in the mouse models studied. Polarized
intestinal epithelial cells (T84) were exposed to DSS in the
presence or absence of hAAT. Within 6 hours of treatment, DSS
induced a 60% reduction in barrier function as measured by TEER
(903 6 64 Vcm2) relative to vehicle. This decrease in TEER was
attenuated by coadministration of DSS and hAAT (1326 6
105 Vcm2), which was partially protective compared with DSS
alone (P , 0.05) (Fig. 7A). Similarly, endothelial cells (human
microvascular endothelial cells) displayed decreased FD70 flux,
an alternative surrogate marker of barrier function, in response to
treatment with lipopolysaccharide (10 mg/mL) after hAAT pretreat-
ment (1.4 6 0.1 versus 0.8 6 0.1; P , 0.01) (Fig. 7B).
We then assessed whether hAAT may also reduce barrier
permeability in diseased animals, as measured by detection of FD4 in
serum 4 hours post-FD4 gavage. In SAMP1 mice with established
ileitis (20 weeks of age), detection of serum FD4 was lower in mice
treated for 9 days with hAAT (0.8 6 0.1 ng/mL) compared with
vehicle controls (1.2 6 0.1 ng/mL; P , 0.05) (Fig. 7C) consistent
with decreased intestinal permeability in these mice. Thus, hAAT
has a protective effect on barrier function both in vitro and in vivo.
FIGURE 4. hAAT expedited recovery from established colitis. A, Weight change during recovery from DSS injury expressed as percentage change
from day 0 of DSS administration. B, Postmortem assessment of colon length from colitic mice treated with (DSS + hAAT) or without hAAT (DSS +
albumin). C, Quantification of cellular infiltrate in indicated organs from colitic mice treated with hAAT or albumin. D, Histological assessment of
colitis from albumin or hAAT-treated mice during recovery from colitis. E, Measurement of secreted cytokines from colonic explants of colitic mice
treated with albumin or hAAT. Data expressed as mean 6 standard error of the mean, n ¼ 6 mice per group; *P , 0.05, **P , 0.01.
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Upregulation of AAT in Intestinal Tissue of
Patients with IBD
Although AAT has long been used as a surrogate marker of
intestinal inflammation in IBD, the expression of AAT in the intestine
of patients with IBD has not been demonstrated to date. Here, we
describe the increased expression of AAT in the intestinal crypts of
tissue of patient with CD by immunohistochemistry (Fig. 8A). This
increased protein expression coincided with a significant upregulation
of AAT messenger RNA from patients with CD (2.4-fold; n ¼ 18;
P, 0.05) relative to healthy controls. This difference was even more
striking in inflamed ileal tissue from patients with CD (3.3-fold; n ¼
7; P, 0.001) (Fig. 8B). Finally to account for the cross-species anti-
inflammatory effect of hAAT, we compared protein sequences and
demonstrated that AAT is highly conserved between mouse and
human. Therefore, AAT is upregulated in intestinal tissue of patients
with CD consistent with attempting to offer protection against over-
active inflammation.
DISCUSSION AND CONCLUSIONS
IBD affects several million people and the most effective
therapies (anti-TNF-a antibodies) work at best in 70% of patients.21
Thus, novel therapies are needed. Here, we demonstrate that human
AAT administration protects mice from acute colitis, enhances
recovery from established colitis, and attenuates spontaneous
chronic ileitis. hAAT-mediated attenuation of inflammation coin-
cided with decreased cytokine production and reduced inflammatory
infiltrate within the affected intestine.
Intestinal inflammation has been associated with a signifi-
cant loss of AAT. Fecal AAT levels positively correlate with
disease severity in CD.22,23 Although stool AAT has been seen
merely as a surrogate marker of decreased intestinal barrier integ-
rity, its loss may also result in considerably lower local AAT
levels. Given the pleiotropic anti-inflammatory effects of the mol-
ecule, this deficit may have negative consequences in IBD. For
example, patients with AAT deficiency and concomitant IBD
develop significantly worse inflammation and are considerably
more likely to require colectomy.14 Although administration of
AAT attenuates inflammation in a number of autoimmune murine
models,10,13 whether this molecule may attenuate intestinal
inflammation had not been explored previously.
We began by examining this question in an acute injury
model of colitis, which results from the administration of DSS.
FIGURE 5. hAAT attenuated ileitis in SAMP1 mice. A, Histological
assessment of 20-week-old SAMP1 mice treated with albumin or
hAAT. Data expressed as mean 6 standard error of the mean, n $ 6
mice per group from a single study reflective of multiple independent
studies; *P , 0.05. B, Representative micrographs showing ileal tissue
morphology in SAMP1 mice from albumin and hAAT-treated animals.
Black scale bars indicate 100 mm.
FIGURE 6. hAAT decreased CD4+ T cells and inflammatory cytokines in
SAMP1 mice. A, The percentages of CD4+, CD8+, and CD19+ lym-
phocytes from indicated organs analyzed by flow cytometry. B, Rep-
resentative dot plots showing percentages of CD4 and CD8
lymphocytes from the MLN and LP of SAMP1 mice treated with
albumin or hAAT. C, Expression of cytokine secretion from ileal tissue
explants from SAMP1 mice treated with albumin or hAAT. Data ex-
pressed as mean 6 standard error of the mean, n ¼ 6 per group, *P ,
0.05, **P , 0.01.
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DSS-induced epithelial damage results in predictable impaired
barrier function,24,25 increased bacterial translocation, and prom-
inent macrophage and neutrophil infiltrates. A key role for endog-
enous AAT is to neutralize neutrophil elastase. Previous studies
had demonstrated increased intestinal elastase activity in both
murine models and patients with IBD.26,27 This is consistent with
the neutrophilic infiltrates, which contribute to the pathogenesis of
IBD. Moreover, specific chemical inhibition of neutrophil elastase
attenuates DSS-induced colitis,26,27 thus attenuation by hAAT in
this model was predictable, based solely on its effect on neutro-
phil elastase. We attempted to address the relative contribution of
neutrophil elastase to the anti-inflammatory effect of hAAT in
DSS colitis, through antibody depletion of neutrophils. Yet, neu-
trophils are such important mediators of inflammation in DSS
colitis that it was not possible to differentiate between the bene-
ficial effect of hAAT alone compared with the effect of neutrophil
depletion (data not shown).
Consistent with a principal role for innate immune mechanisms
in this model, all the cytokines that were decreased after hAAT
treatment (IL-6, CXCL1, MCP-1) are produced by neutrophils and/or
macrophages. In contrast, in human IBD, the chronic nature of disease
strongly implicates the adaptive immune response in the perpetuation
of disease. Thus, we additionally investigated the potential therapeutic
efficacy of AAT in SAMP1 mice, a spontaneous chronic murine
model of ileitis in which effector CD4+ T cells play a central role.17
Drugs with potent anti-inflammatory effects in this model, as in human
IBD, have pleiotropic anti-inflammatory activities acting though mul-
tiple mechanisms in concert. In that context, we would have expected
that the benefit of a molecule that strictly neutralizes neutrophil elastase
should be limited. Our experiments demonstrate that this was not the
case. Treatment with hAAT reversed chronic intestinal inflammation
in these mice, independent of changes in neutrophil numbers but
associated with decreased intestinal CD4+ T cells and consistent with
previous anti-inflammatory studies in chronic murine ileitis.28 There
was also a concomitant decrease in proinflammatory cytokines
(i.e., TNF-a and IL-17) secreted from the ilea of hAAT-treated mice.
Blockade of proinflammatory cytokines, such as TNF-a, has
proven highly effective in the treatment of IBD.29 This cytokine has
multiple proinflammatory effects at sites of inflammation.21,30
Proinflammatory cytokines increase intestinal permeability through
FIGURE 7. Intestinal barrier function is protected by hAAT administration. A, Measurement of TEER across confluent intestinal epithelial mono-
layers grown on permeable supports and treated with either vehicle or hAAT alone or with concomitant DSS injury as an indirect indicator of
epithelial barrier function. B, Fluorometric assessment of fluorescein isothiocyanate-dextran flux across an endothelial cell monolayer treated with
and without hAAT and concomitantly challenged with or without lipopolysaccharide (LPS). C, Fluorescent detection of fluorescein isothiocyanate-dextran,
a surrogate marker for in vivo intestinal permeability, measured in serum of SAMP1 mice treated with albumin or hAAT. *P , 0.05, **P , 0.01.
FIGURE 8. Increased expression of hAAT in the intestine of patients with
IBD. A, Immunohistochemical detection of hAAT expression in control and
patient with CD intestinal biopsies demonstrates an increased expression
predominately localized to the intestinal crypts. B, Real-time PCR analysis
of hAAT messenger RNA expression in human intestinal tissue demon-
strates a significant upregulation of hAAT in the intestine of IBD. C,
Sequence analysis of hAAT expression compared with that of mouse AAT
demonstrates strong homology by basic local alignment. Data expressed
as mean +/2 standard error of the mean; *P , 0.05, ***P , 0.001.
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targeting of intestinal epithelial31 and endothelial cells,20 which in
turn increases translocation of luminal antigens and exacerbates
activation of resident leukocytes. Locally secreted cytokines also
increase the endothelial expression of adhesion molecules,32 per-
petuating inflammation through increased leukocyte recruitment
thereby further increasing proinflammatory cytokine secretion and
worsening epithelial injury. This deficit in intestinal barrier integrity
is closely associated with disease severity.33 The anti-inflammatory
effect of AAT on the ileitis of SAMP1 mice, like that of TNF-a
inhibition, is most likely multifactorial, dependent in part on its
inhibition of cytokine production and partly on the restoration of
intestinal barrier function, both interconnected mechanisms which
are critical in this model.34
Given the clear therapeutic potential of AAT supplemen-
tation in murine models, we next chose to assess levels of
endogenous AAT in patients with IBD. Although we might have
anticipated that patients with IBD were deficient in this natural
anti-inflammatory, our data demonstrates an increase in AAT at
both messenger RNA and protein levels in tissues of patient with
IBD. The localization of AAT seems consistent with the previous
description of paneth cell6 expression of AAT and also seems to
occur to a greater extent in the subset of patients with CD with
ileal involvement. It may be that the upregulation of AAT is an
attempt to counteract the excessive loss of the anti-inflammatory
AAT associated with IBD. Lessons learned from the IL-1 field
have demonstrated that although IL-1 receptor antagonist, another
endogenous anti-inflammatory molecule, is significantly upregu-
lated in chronic diseases such as rheumatoid arthritis,35 neverthe-
less further supplementation has proven beneficial for the delay of
joint erosion in these patients.36
The potential anti-inflammatory role of AAT in preclinical
models and human IBD had not been explored previously. Yet
based on its known effect on neutrophil elastase, a therapeutic
effect on DSS-induced injury was anticipated. However, its anti-
inflammatory role in a chronic model of ileitis is an entirely novel
finding. The therapeutic benefit seen in these studies using an
endogenous anti-inflammatory molecule, which lacks the immuno-
genicity of other biologicals and has a long-standing safety record,
makes this a potential novel approach for the treatment of IBD.
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